Pacific Edge Limited (NZE:PEB)

New Zealand flag New Zealand · Delayed Price · Currency is NZD
0.0980
-0.0010 (-1.01%)
Jun 6, 2025, 4:25 PM NZST
-2.00%
Market Cap 80.38M
Revenue (ttm) 22.75M
Net Income (ttm) -29.94M
Shares Out 811.92M
EPS (ttm) -0.04
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 109,340
Average Volume 466,358
Open 0.0990
Previous Close 0.0990
Day's Range 0.0970 - 0.1000
52-Week Range 0.0500 - 0.1850
Beta 0.69
RSI 57.00
Earnings Date May 23, 2025

About Pacific Edge

Pacific Edge Limited, a cancer diagnostics company, engages in development and commercialization of bladder cancer diagnostic and prognostic tests for patients. It operates through two segments, Commercial and Research. The company offers Cxbladder, a genomic urine biomarker test for the detection and surveillance of bladder cancer. It also develops Cxbladder Triage, a frontline diagnostic product that helps de-intensify clinical work-up for patients with haematuria who have a low probability of bladder cancer; and Cxbladder Monitor, a non-inva... [Read more]

Industry Medical - Diagnostics & Research
Sector Healthcare
Founded 2001
Employees 114
Stock Exchange New Zealand Stock Exchange
Ticker Symbol PEB
Full Company Profile

Financial Performance

In 2024, Pacific Edge's revenue was 24.67 million, a decrease of -2.20% compared to the previous year's 25.23 million. Losses were -29.94 million, 1.36% more than in 2023.

Financial Statements

News

Half Year 2025 Pacific Edge Ltd Earnings Call Transcript

Half Year 2025 Pacific Edge Ltd Earnings Call Transcript

6 months ago - GuruFocus